CompletedNCT00254748
The Effect of Quetiapine on Psychotic-Like Symptoms in Borderline Personality Disordered Patients: A study
It tested quetiapine fumarate for Borderline Personality Disorder.
Personality disorders, Borderline personalityDrugFrom 18 Years to 55 Years
Understand this study
Who was this study for?
Listed age limits: 18 years to 55 years.
- Listed locations
- Apeldoorn, Netherlands · Nijmegen, Netherlands and 1 more locationSee all locations and recruitment
Compensation and expense reimbursement have not been verified for this summary.
Study information
Study start dateJune 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 40
- Sponsor
- AstraZeneca
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Netherlands
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT00254748
- Official title
- The Effect of Quetiapine on Psychotic-Like Symptoms in Borderline Personality Disordered Patients: A Randomised Placebo-Controlled Trial
Recruitment & locations
CompletedApeldoorn · Nijmegen · Veghel
Registry details
Registry conditions (original wording)
Borderline Personality Disorder
Questions about this study
Who is behind this study?
The study sponsor is AstraZeneca.
Did this study involve medication?
Yes. The study involved medication, including Quetiapine fumarate and Placebo.
Who was this study for?
Listed age limits: 18 years to 55 years.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit me